Management of Pulmonary Arterial Hypertension in the Neonatal Unit

被引:11
|
作者
Krishnan, Usha [1 ]
机构
[1] New York Med Coll, Dept Pediat Cardiol, Valhalla, NY 10595 USA
关键词
pulmonary hypertension; persistent pulmonary hypertension in the newborn; chronic lung disease of infancy; sildenafil; bosentan; CHRONIC LUNG-DISEASE; NITRIC-OXIDE; SILDENAFIL; NEWBORN; PATHOGENESIS; DIAGNOSIS; CHILDREN; INFANTS; GROWTH; INJURY;
D O I
10.1097/CRD.0b013e3181ce9edb
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This review article discusses the pathophysiology and management of pulmonary hypertension (PH) in the newborn unit. The discussion revolves around 2 aspects: persistent pulmonary hypertension in the newborn, which is seen in the first few weeks of life, and PH associated with chronic lung disease in the post neonatal period of infancy. Although the etiopathogenesis as well as prognosis for infantile PH differ from older children and adults, the basic principles of management are similar. Inhaled nitric oxide, intravenous prostacyclin and its analogs, and oral medications like sildenafil and endothelin receptor blockers play a very important role in PH management in the newborn unit, in addition to ventilation strategies and acid-based balance management.
引用
收藏
页码:73 / 75
页数:3
相关论文
共 50 条
  • [21] Evidence-based Pharmacologic management of pulmonary arterial hypertension
    Benedict, Neal
    Seybert, Amy
    Mathier, Michael A.
    CLINICAL THERAPEUTICS, 2007, 29 (10) : 2134 - 2153
  • [22] Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update
    Wong, Alexandra K.
    Channick, Richard N.
    DRUG HEALTHCARE AND PATIENT SAFETY, 2019, 11 : 71 - 85
  • [23] Current Management and Future Directions for Pulmonary Arterial Hypertension Associated with Congenital Heart Disease
    Mahmoud, Ahmed K.
    Abbas, Mohammed Tiseer
    Kamel, Moaz A.
    Farina, Juan M.
    Pereyra, Milagros
    Scalia, Isabel G.
    Barry, Timothy
    Chao, Chieh-Ju
    Marcotte, Francois
    Ayoub, Chadi
    Scott, Robert L.
    Majdalany, David S.
    Arsanjani, Reza
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (01):
  • [24] Update on Perioperative Pediatric Pulmonary for Hypertension Management
    Wadia, Rajeev S.
    Bernier, Meghan L.
    Diaz-Rodriguez, Natalia
    Goswami, Dheeraj K.
    Nyhan, Sinead M.
    Steppan, Jochen
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2022, 36 (03) : 667 - 676
  • [25] Neonatal Pulmonary Hypertension: Phenotypes, Physiology, and Management
    Lakshminrusimha, Satyan
    Abman, Steven H.
    CLINICS IN PERINATOLOGY, 2024, 51 (01)
  • [26] Management of Pulmonary Arterial Hypertension
    Jennalyn D. Mayeux
    Irene Z. Pan
    John Dechand
    Joshua A. Jacobs
    Tara L. Jones
    Stephen H. McKellar
    Emily Beck
    Nathan D. Hatton
    John J. Ryan
    Current Cardiovascular Risk Reports, 2021, 15
  • [27] Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy
    Ghofrani, Hossein A.
    Morrell, Nicholas W.
    Hoeper, Marius M.
    Olschewski, Horst
    Peacock, Andrew J.
    Barst, Robyn J.
    Shapiro, Shelley
    Golpon, Heiko
    Toshner, Mark
    Grimminger, Friedrich
    Pascoe, Steve
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 182 (09) : 1171 - 1177
  • [28] Management of Pulmonary Arterial Hypertension in the Pediatric Patient
    Jordan E. Ezekian
    Kevin D. Hill
    Current Cardiology Reports, 2019, 21
  • [29] Management of Pulmonary Arterial Hypertension
    Mayeux, Jennalyn D.
    Pan, Irene Z.
    Dechand, John
    Jacobs, Joshua A.
    Jones, Tara L.
    McKellar, Stephen H.
    Beck, Emily
    Hatton, Nathan D.
    Ryan, John J.
    CURRENT CARDIOVASCULAR RISK REPORTS, 2021, 15 (01)
  • [30] Bosentan in Pediatric Patients with Pulmonary Arterial Hypertension
    Beghetti, Maurice
    CURRENT VASCULAR PHARMACOLOGY, 2009, 7 (02) : 225 - 233